Feasibility study of ramucirumab plus irinotecan in patients with advanced gastric cancer
- Conditions
- chemo-refractory gastric cancer
- Registration Number
- JPRN-UMIN000019075
- Lead Sponsor
- Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Not provided
1. History of another malignancy which could affect compliance with the protocol or interpretation of result of the study. 2. Previous systemic chemotherapy with irinotecan. 3. Uncontrolled arterial hypertension (e.g. >= 150 / >= 90 mmHg despite standard medical management) 4. Active infection requiring intravenous antibiotics at entry. 5. Serious illness or medical conditions. 6. Uncontrolled diarrhea which disrupt daily life despite fully medical management. 7. History of severe allergy or hypersensitivity for any drugs. 8. Moderate or large ascites or pleural effusion. 9. Chronic daily treatment with oral cortisteroid treatment. 10. Evidence of psychological disorder. 11. Symptomatic evidence of known central nervous system metastases or carcinomatous meningitis. 12. Daily treatment with atazanavir sulfate. 13. Pregnant or breastfeeding, or unwilling to practice contraception during the study. 14. Known acute or choric-active infection with HBV or HCV. 15. Any condition that suggest that the patient is, in the investigator's opinion, not an appropriate candidate for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method